$199advertised
GLP-1 Injections
$99 for the first month
Billing term not stated, so we do not compare it
2 figures published, none with a billing term
✓ Figure read 5 Nov 2026
Head-to-head comparison
MEDVi's lowest advertised GLP-1 figure is $199, after $99 for the first month, checked 5 Nov 2026. It does not state how long a plan runs. At its lowest dated price, Ivim Health costs $139.99 a month (12-month plan, $780 for the medication at this rate): $65 for medication plus a $74.99 membership fee, checked 16 Nov 2026. We don't call either one cheaper. The figures are not like for like: MEDVi's figure names no product we can match; MEDVi's membership fee is not established; Ivim Health does not say whether it bills its program monthly or up front.
They differ on 3 of the 7 things we track. On the other 4, we lack the fact for one of them or both.
We earn a commission on paid links. How we make money
We track prices, terms and availability. We are not clinicians, this page is not medically reviewed, and nothing here is medical advice. Talk to a licensed clinician about whether a GLP-1 medication is right for you.
$199advertised
GLP-1 Injections
$99 for the first month
Billing term not stated, so we do not compare it
2 figures published, none with a billing term
✓ Figure read 5 Nov 2026
First year, all in
$139.99/mo total, 12-month plan
Price checked 16 Nov 2026
FDA letter, Feb 2026 8.7/10 VerifiedDose scoreMore columns to the right. Drag or swipe the table.
| Term |
|
|
|---|---|---|
| From $/mo | not published | $65 compounded semaglutide, 12-month plan Verified 16 Nov 2026 |
| Membership fee | not published | $74.99 Verified 16 Nov 2026 |
| Insurance | Files no insurance claims | Files insurance claims |
| Cancellation | Message or call support | Online, self-service |
| Model | Compounded | Hybrid |
Rows where both providers state the same thing are left out on purpose. Every price here carries the date we read it from the provider's own pages; a figure with no date reads "not published" rather than being estimated. Not on file for either provider: states covered, time to prescription.
A lower price does not establish clinical suitability or quality of care. We compare what these companies publish about cost and terms, and nothing here measures the medicine or the service behind it.
Verdict: MEDVi and Ivim Health both sell compounded GLP-1 medication, but their prices do not line up. MEDVi names no molecule and no plan length beside its prices, and Ivim labels its prices 12 months. Ivim adds a monthly membership that runs as long as your program; MEDVi's fee is not one we could establish. Ivim lets you cancel online; MEDVi asks you to contact customer service. Both records carry an FDA warning letter from February 2026.
MEDVi prices "GLP-1 Injections" and "GLP-1 Tablets" as starting figures, with no molecule and no plan length beside them. Ivim prices compounded semaglutide and tirzepatide on programs labelled 12 months, without saying whether they are billed monthly or up front.
MEDVi's compounded program page says it has no membership or hidden fees, while its brand-name cards add a membership, so we hold no single fee for it. MEDVi says all its prescriptions are cash-pay, and you cancel by contacting customer service. Ivim's membership must run the length of your program, and you can cancel it online.
Its price cards say GLP-1 injections and GLP-1 tablets without naming the molecule. We list those figures as advertised, with their dates.
Yes. FDA sent each a warning letter in February 2026. Both are listed below with their sources.
Ratings weigh verified price, total first-year cost, state availability, speed to prescription, cancellation terms and regulatory record. Full scoring rubric.
We are not clinicians and this page carries no clinical review. Drug and regulatory facts are cited directly from FDA, CMS and court records, never a provider's marketing claims.
When you sign up with a provider through our links, we may earn a referral fee. Fees never influence a rating, a price, or a position in a table. Full advertiser disclosure.